Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which...

|By:, SA News Editor

Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%.